CN102827841A - 利用小干扰rna抑制病毒基因表达 - Google Patents

利用小干扰rna抑制病毒基因表达 Download PDF

Info

Publication number
CN102827841A
CN102827841A CN2012102773452A CN201210277345A CN102827841A CN 102827841 A CN102827841 A CN 102827841A CN 2012102773452 A CN2012102773452 A CN 2012102773452A CN 201210277345 A CN201210277345 A CN 201210277345A CN 102827841 A CN102827841 A CN 102827841A
Authority
CN
China
Prior art keywords
seq
sequence
shrna
sirna
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012102773452A
Other languages
English (en)
Chinese (zh)
Inventor
R·L·卡斯帕尔
H·伊尔韦斯
A·A·塞伊汗
A·V·弗拉索夫
B·H·约翰斯顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somagenics Inc
Original Assignee
Somagenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2005/032768 external-priority patent/WO2006031901A2/en
Application filed by Somagenics Inc filed Critical Somagenics Inc
Publication of CN102827841A publication Critical patent/CN102827841A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2012102773452A 2005-09-12 2006-06-01 利用小干扰rna抑制病毒基因表达 Pending CN102827841A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US2005/032768 2005-09-12
PCT/US2005/032768 WO2006031901A2 (en) 2004-09-10 2005-09-12 SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2006800418459A Division CN101305095B (zh) 2005-09-12 2006-06-01 利用小干扰rna抑制病毒基因表达

Publications (1)

Publication Number Publication Date
CN102827841A true CN102827841A (zh) 2012-12-19

Family

ID=37708176

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2012102773452A Pending CN102827841A (zh) 2005-09-12 2006-06-01 利用小干扰rna抑制病毒基因表达
CN2006800418459A Expired - Fee Related CN101305095B (zh) 2005-09-12 2006-06-01 利用小干扰rna抑制病毒基因表达

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2006800418459A Expired - Fee Related CN101305095B (zh) 2005-09-12 2006-06-01 利用小干扰rna抑制病毒基因表达

Country Status (9)

Country Link
EP (1) EP1979480A2 (de)
JP (1) JP2009521207A (de)
KR (1) KR20090003147A (de)
CN (2) CN102827841A (de)
AU (1) AU2006291568A1 (de)
BR (1) BRPI0615717A2 (de)
CA (1) CA2622242A1 (de)
RU (1) RU2008114304A (de)
WO (1) WO2007032794A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042115A2 (en) * 2007-09-24 2009-04-02 Rosetta Inpharmatics Llc Methods of designing short hairpin rnas (shrnas) for gene silencing
PT2341943T (pt) * 2008-09-22 2019-02-06 Dicerna Pharmaceuticals Inc Composições e métodos para a inibição específica de expressão génica por dsrna que possui modificações
WO2010045384A2 (en) 2008-10-15 2010-04-22 Somagenics Inc. Short hairpin rnas for inhibition of gene expression
CN102325534B (zh) * 2008-12-18 2016-02-17 戴瑟纳制药公司 延长的dicer酶底物和特异性抑制基因表达的方法
EP2454371B1 (de) 2009-07-13 2021-01-20 Somagenics, Inc. Chemische modifikation kleiner haarnadel-rnas zur genexpressionshemmung
EP4079856A1 (de) * 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
KR101668954B1 (ko) 2015-05-29 2016-10-24 연세대학교 산학협력단 ＨＣＶ ＩＲＥＳ를 표적으로 하는 Ｃ형 간염 바이러스 치료제 siRNA
BR112019012057A2 (pt) * 2016-12-15 2019-11-12 Meharry Medical College agente antiviral, composição farmacêutica para a administração do mesmo e métodos de redução na replicação do vírus zika (zikv) e tratamento de doença mediada pelo vírus zika (zikv)
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
US11492623B2 (en) 2018-08-13 2022-11-08 Alnylam Pharmaceuticals, Inc. Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070750A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc Rna interference mediated inhibition of hepatitis c virus
CN1631443A (zh) * 2004-09-22 2005-06-29 广州拓谱基因技术有限公司 用于预防或治疗丙型肝炎的靶向小干扰rna制剂及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031901A2 (en) * 2004-09-10 2006-03-23 Somagenics, Inc. SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070750A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc Rna interference mediated inhibition of hepatitis c virus
CN1631443A (zh) * 2004-09-22 2005-06-29 广州拓谱基因技术有限公司 用于预防或治疗丙型肝炎的靶向小干扰rna制剂及其制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RADHAKRISHNAN等: "RNA interference as a new strategy against viral hepatitis", 《VIROLOGY》 *
YOKOTA TAKANORI 等: "Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs.", 《EMBO REPORTS》 *
吴叔文等: "细胞内表达的小干扰RNA靶向丙肝病毒5′保守区的研究", 《中国病毒学》 *

Also Published As

Publication number Publication date
AU2006291568A1 (en) 2007-03-22
RU2008114304A (ru) 2009-11-20
CA2622242A1 (en) 2007-03-22
WO2007032794A2 (en) 2007-03-22
CN101305095B (zh) 2012-09-26
WO2007032794A3 (en) 2007-08-30
JP2009521207A (ja) 2009-06-04
CN101305095A (zh) 2008-11-12
BRPI0615717A2 (pt) 2011-05-24
EP1979480A2 (de) 2008-10-15
KR20090003147A (ko) 2009-01-09

Similar Documents

Publication Publication Date Title
CN101305095B (zh) 利用小干扰rna抑制病毒基因表达
US8426380B2 (en) Inhibition of viral gene expression using small interfering RNA
Kanda et al. Small Interfering RNA Targeted to Hepatitis C Virus 5′ NontranslatedRegion Exerts Potent Antiviral Effect
Jiang et al. Picornavirus morphogenesis
Wilson et al. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region
You et al. A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication
US10982212B2 (en) Conserved HBV and HCV sequences useful for gene silencing
JP4980716B2 (ja) 遺伝子サイレンシングに有用な保存されたｈｂｖ及びｈｃｖ配列
JP5934310B2 (ja) 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列
Kopek et al. Nodavirus-induced membrane rearrangement in replication complex assembly requires replicase protein a, RNA templates, and polymerase activity
Merkle et al. Biological significance of a human enterovirus B-specific RNA element in the 3′ nontranslated region
Du et al. Hepatitis C virus replicative double-stranded RNA is a potent interferon inducer that triggers interferon production through MDA5
Zekri et al. Consensus siRNA for inhibition of HCV genotype-4 replication
KR100733186B1 (ko) Ｈｃｖ 유전자에 특이적인 작은 간섭 ｒｎａ 및 그를유효성분으로 포함하는 ｃ형 간염 치료제
Shier et al. Effect of RNA interference on the hepatitis C virus core expression in HepG2/C3A cells using genotype 4 isolates from Saudi patients
Barnard Genetic Determinants of Coxsackievirus B3 Pathogenesis
MX2008003504A (en) Inhibition of viral gene expression using small interfering rna
Antón Leonardo Mina Ibarra

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121219